Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent.
Clonidine hydrochloride is a new antihypertensive agent with a primary site of action in the central nervous system. When administered with a diuretic, it is effective for long-term therapy and may be particularly useful in patients with moderately severe hypertension. Clonidine is comparable to methyldopa in efficacy but may cause side-effects more frequently. The only potentially serious adverse reaction that has been reported is a rebound increase in blood pressure that may occur following rapid withdrawal.
D000284:Administration, Oral; D001794:Blood Pressure; D002302:Cardiac Output; D003000:Clonidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004341:Drug Evaluation; D004357:Drug Synergism; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007275:Injections, Intravenous; D008750:Methyldopa / Q000627:therapeutic use; D011187:Posture; D013375:Substance Withdrawal Syndrome; D014655:Vascular Resistance
D004232:Diuretics; D008750:Methyldopa; D003000:Clonidine